Literature DB >> 10554108

Inhibition of succinimide formation in aqueous Zn-rHirudin suspensions.

U Gietz1, T Arvinte, R Alder, H P Merkle.   

Abstract

PURPOSE: The formation of succinimide intermediates at Asp-Gly sites and their hydrolysis products, e.g., isoAsp isomers, represents a common source of microheterogeneity in therapeutic proteins. Here we report on the stabilization effect of a zinc chloride induced precipitation of recombinant hirudin HV1 (rHir), an anticoagulant protein.
METHODS: rHir was precipitated by zinc chloride at neutral pH to form a Zn-rHir suspension. An Arrhenius-type study (at 50, 40, 30, and 25 degrees C) and a 4 degrees C stability study were performed. Monitoring of rHir, rHir succinimides at Asp33-Gly34 (Q5) and Asp53-Gly54 (Q4), and further side products was by capillary electrophoresis (CE).
RESULTS: The activation energies of rHir degradation in both aqueous rHir solution and Zn-rHir suspension were similar, i.e. 104.5 and 110.3 kJ/mol, respectively. Zn-rHir suspension demonstrated improved shelf-life stability (t90%, 95% confidence limit) versus rHir solution, i.e., 23 versus 3 days at 25 degrees C and 292 versus 147 days at 4 degrees C, respectively. In rHir solution, Q4 (Asp53-Gly54 succinimide) levels were slightly above Q5 (Asp33-Gly34 succinimide) levels. In Zn-rHir suspension, however, Q4 succinimide levels dropped markedly whereas Q5 levels were not affected. Correspondingly, in Zn-rHir isoAsp53-rHir levels were reduced but not isoAsp33-rHir levels.
CONCLUSIONS: In Zn-rHir suspensions, interactions of zinc and rHir show site-specific inhibition of succinimide formation only at Asp53-Gly54 (Q4), located in the highly flexible C-terminal tail of rHir. In contrast, succinimide formation at Asp33-Gly34 (Q5), located in a less flexible loop domain is not affected, reflecting steric hindrance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10554108     DOI: 10.1023/a:1018925209080

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  13 in total

1.  Characterization of the deamidated forms of recombinant hirudin.

Authors:  A Tuong; M Maftouh; C Ponthus; O Whitechurch; C Roitsch; C Picard
Journal:  Biochemistry       Date:  1992-09-08       Impact factor: 3.162

2.  Degradation of synthetic salmon calcitonin in aqueous solution.

Authors:  K C Lee; Y J Lee; H M Song; C J Chun; P P DeLuca
Journal:  Pharm Res       Date:  1992-11       Impact factor: 4.200

Review 3.  Recombinant hirudin: genetic engineering and structure analysis.

Authors:  W E Märki; H Grossenbacher; M G Grütter; M H Liersch; B Meyhack; J Heim
Journal:  Semin Thromb Hemost       Date:  1991-04       Impact factor: 4.180

4.  Chemical pathways of peptide degradation. II. Kinetics of deamidation of an asparaginyl residue in a model hexapeptide.

Authors:  K Patel; R T Borchardt
Journal:  Pharm Res       Date:  1990-07       Impact factor: 4.200

5.  Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters.

Authors:  P Zoldhelyi; M W Webster; V Fuster; D E Grill; D Gaspar; S J Edwards; C F Cabot; J H Chesebro
Journal:  Circulation       Date:  1993-11       Impact factor: 29.690

6.  Characterization of a beta-Asp33 isoform of recombinant hirudin sequence variant 1 by low-energy collision-induced dissociation.

Authors:  P Schindler; D Müller; W Märki; H Grossenbacher; W J Richter
Journal:  J Mass Spectrom       Date:  1996-09       Impact factor: 1.982

7.  Chemical pathways of peptide degradation. IV. Pathways, kinetics, and mechanism of degradation of an aspartyl residue in a model hexapeptide.

Authors:  C Oliyai; R T Borchardt
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

8.  Separation of r-hirudin from similar substances by capillary electrophoresis.

Authors:  C Dette; H Wätzig
Journal:  J Chromatogr A       Date:  1995-05-12       Impact factor: 4.759

9.  Inactivation kinetics of enzyme pharmaceuticals in aqueous solution.

Authors:  S Yoshioka; K Izutsu; Y Aso; Y Takeda
Journal:  Pharm Res       Date:  1991-04       Impact factor: 4.200

10.  Characterization of succinimide-type dehydration products of recombinant hirudin variant 1 by electrospray tandem mass spectrometry.

Authors:  H Grossenbacher; W Märki; M Coulot; D Müller; W J Richter
Journal:  Rapid Commun Mass Spectrom       Date:  1993-12       Impact factor: 2.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.